Literature DB >> 18729824

Accommodation of physostigmine and its analogues by acetylcholinesterase is dominated by hydrophobic interactions.

Dov Barak1, Arie Ordentlich, Dana Stein, Qian-Sheng Yu, Nigel H Greig, Avigdor Shafferman.   

Abstract

The role of the functional architecture of the HuAChE (human acetylcholinesterase) in reactivity toward the carbamates pyridostigmine, rivastigmine and several analogues of physostigmine, that are currently used or considered for use as drugs for Alzheimer's disease, was analysed using over 20 mutants of residues that constitute the interaction subsites in the active centre. Both steps of the HuAChE carbamylation reaction, formation of the Michaelis complex as well as the nucleophilic process, are sensitive to accommodation of the ligand by the enzyme. For certain carbamate/HuAChE combinations, the mode of inhibition shifted from a covalent to a noncovalent type, according to the balance between dissociation and covalent reaction rates. Whereas the charged moieties of pyridostigmine and rivastigmine contribute significantly to the stability of the corresponding HuAChE complexes, no such effect was observed for physostigmine and its analogues, phenserine and cymserine. Moreover, physostigmine-like ligands carrying oxygen instead of nitrogen at position -1 of the tricyclic moiety (physovenine and tetrahydrofurobenzofuran analogues) displayed comparable structure-function characteristics toward the various HuAChE enzymes. The essential role of the HuAChE hydrophobic pocket, comprising mostly residues Trp(86) and Tyr(337), in accommodating (-)-physostigmine and in conferring approximately 300-fold stereoselectivity toward physostigmines, was elucidated through examination of the reactivity of selected HuAChE mutations toward enantiomeric pairs of different physostigmine analogues. The present study demonstrates that certain charged and uncharged ligands, like analogues of physostigmine and physovenine, seem to be accommodated by the enzyme mostly through hydrophobic interactions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18729824      PMCID: PMC2949283          DOI: 10.1042/BJ20081276

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  38 in total

1.  Structural determinants of Torpedo californica acetylcholinesterase inhibition by the novel and orally active carbamate based anti-alzheimer drug ganstigmine (CHF-2819).

Authors:  Cecilia Bartolucci; Mariacristina Siotto; Eleonora Ghidini; Gabriele Amari; Pier Tonino Bolzoni; Marco Racchi; Gino Villetti; Maurizio Delcanale; Doriano Lamba
Journal:  J Med Chem       Date:  2006-08-24       Impact factor: 7.446

2.  Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine.

Authors:  P Bar-On; C B Millard; M Harel; H Dvir; A Enz; J L Sussman; I Silman
Journal:  Biochemistry       Date:  2002-03-19       Impact factor: 3.162

3.  Does "butyrylization" of acetylcholinesterase through substitution of the six divergent aromatic amino acids in the active center gorge generate an enzyme mimic of butyrylcholinesterase?

Authors:  D Kaplan; A Ordentlich; D Barak; N Ariel; C Kronman; B Velan; A Shafferman
Journal:  Biochemistry       Date:  2001-06-26       Impact factor: 3.162

4.  Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II.

Authors:  G Kryger; M Harel; K Giles; L Toker; B Velan; A Lazar; C Kronman; D Barak; N Ariel; A Shafferman; I Silman; J L Sussman
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2000-11

Review 5.  A review of rivastigmine: a reversible cholinesterase inhibitor.

Authors:  Bradley R Williams; Arlette Nazarians; Mark A Gill
Journal:  Clin Ther       Date:  2003-06       Impact factor: 3.393

6.  The aromatic "trapping" of the catalytic histidine is essential for efficient catalysis in acetylcholinesterase.

Authors:  Dov Barak; Dana Kaplan; Arie Ordentlich; Naomi Ariel; Baruch Velan; Avigdor Shafferman
Journal:  Biochemistry       Date:  2002-07-02       Impact factor: 3.162

7.  Stereoselectivity toward VX is determined by interactions with residues of the acyl pocket as well as of the peripheral anionic site of AChE.

Authors:  Arie Ordentlich; Dov Barak; Gali Sod-Moriah; Dana Kaplan; Dana Mizrahi; Yoffi Segall; Chanoch Kronman; Yishai Karton; Arie Lazar; Dino Marcus; Baruch Velan; Avigdor Shafferman
Journal:  Biochemistry       Date:  2004-09-07       Impact factor: 3.162

Review 8.  Cholinesterase inhibitors: new roles and therapeutic alternatives.

Authors:  Ezio Giacobini
Journal:  Pharmacol Res       Date:  2004-10       Impact factor: 7.658

9.  The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates.

Authors:  Efrat Groner; Yacov Ashani; Donna Schorer-Apelbaum; Jeffrey Sterling; Yaacov Herzig; Marta Weinstock
Journal:  Mol Pharmacol       Date:  2007-03-08       Impact factor: 4.436

Review 10.  Acetylcholinesterase: a multifaceted target for structure-based drug design of anticholinesterase agents for the treatment of Alzheimer's disease.

Authors:  Harry M Greenblatt; Hay Dvir; Israel Silman; Joel L Sussman
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 2.866

View more
  8 in total

1.  Kinetics of Torpedo californica acetylcholinesterase inhibition by bisnorcymserine and crystal structure of the complex with its leaving group.

Authors:  Cecilia Bartolucci; Jure Stojan; Qian-sheng Yu; Nigel H Greig; Doriano Lamba
Journal:  Biochem J       Date:  2012-06-01       Impact factor: 3.857

2.  In vitro inhibitory profile of NDGA against AChE and its in silico structural modifications based on ADME profile.

Authors:  Chandran Remya; Kalarickal Vijayan Dileep; Ignatius Tintu; Elessery Jayadevi Variyar; Chittalakkottu Sadasivan
Journal:  J Mol Model       Date:  2012-11-16       Impact factor: 1.810

3.  Pharmacophore-based design and discovery of (-)-meptazinol carbamates as dual modulators of cholinesterase and amyloidogenesis.

Authors:  Qiong Xie; Zhaoxi Zheng; Biyun Shao; Wei Fu; Zheng Xia; Wei Li; Jian Sun; Wei Zheng; Weiwei Zhang; Wei Sheng; Qihong Zhang; Hongzhuan Chen; Hao Wang; Zhuibai Qiu
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

Review 4.  Drugs and pharmaceuticals: management of intoxication and antidotes.

Authors:  Silas W Smith
Journal:  EXS       Date:  2010

5.  In Silico and Ex Vivo Analyses of the Inhibitory Action of the Alzheimer Drug Posiphen and Primary Metabolites with Human Acetyl- and Butyrylcholinesterase Enzymes.

Authors:  Sidra Batool; Tiyyaba Furqan; Muhammad Sibte Hasan Mahmood; David Tweedie; Mohammad A Kamal; Nigel H Greig
Journal:  ACS Pharmacol Transl Sci       Date:  2022-01-12

6.  Multicomponent and multicatalytic asymmetric synthesis of furo[2,3-b]pyrrole derivatives: further insights into the mode of action of chiral phosphoric acid catalysts.

Authors:  Lara Cala; Pedro Villar; Ángel R de Lera; Francisco J Fañanás; Rosana Álvarez; Félix Rodríguez
Journal:  Chem Sci       Date:  2020-08-12       Impact factor: 9.825

7.  How does curcumin work with poor bioavailability? Clues from experimental and theoretical studies.

Authors:  Liang Shen; Cui-Cui Liu; Chun-Yan An; Hong-Fang Ji
Journal:  Sci Rep       Date:  2016-02-18       Impact factor: 4.379

8.  Discovery of new acetylcholinesterase inhibitors for Alzheimer's disease: virtual screening and in vitro characterisation.

Authors:  Benoit David; Pascal Schneider; Philipp Schäfer; Jörg Pietruszka; Holger Gohlke
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.